CDMO Strategy Shift: The Modality Realignment Investors Can’t Ignore
In the dynamic world of biopharmaceutical manufacturing, not all profound changes arrive with a fanfare of press releases. Often, the most significant shifts occur quietly, behind the scenes, as companies strategically recalibrate their positions in response to evolving market forces. Since late 2023, the Contract Development and Manufacturing Organization (CDMO) sector has been undergoing […]